

- **Full Name:** Se Hoon Park
 - **Current Position & Affiliation:** Professor, Samsung Medical Center,
Sungkyunkwan University School of Medicine
 - **Country:** Republic of Korea
-

• Educational Background:

- 2010 Feb **PhD**, Gachon University of Medicine and Science, Incheon, Korea
(Thesis “Novel preclinical model of hepatocellular carcinoma to explore molecular targets for tailored therapy” / Professor Dong Bok Shin)
- 2004 Feb MSc in Medicine, Sungkyunkwan University, Seoul, Korea
- 1994 Feb BSc in Medicine, Konkuk University, Seoul, Korea

• Professional Experience:

- 2010 Mar - present **Professor**, Division of Hematology-Oncology, Department of
Medicine, Sungkyunkwan University, Samsung Medical Center,
Seoul, Korea
- 2010 Sep- 2012 Aug Research Scholar, Harvard School of Public Health, Boston, MA
- 2008 Feb - 2010 Feb Assistant Professor, Sungkyunkwan University, Seoul, Korea
- 2004 Mar - 2008 Jan Assistant Professor, Gachon University, Incheon, Korea

• Professional Organizations:**• Main Scientific Publications:**

1. (2012) Kang JH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. (corresponding author).
2. (2014) Park SH. Second-line chemotherapy for patients with oesophagogastric adenocarcinoma. Lancet Oncol.
3. (2015) Park SH, et al. A phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the ARTIST trial, including survival and subset analyses. J Clin Oncol.
4. (2015) Park SH, et al. Phase Ib trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer. Mol Ther.
5. (2017) Lim SH, et al. Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. Asia Pac J Clin Oncol. (corresponding author).

6. (2017) Jang J, et al. Development of novel patient-derived preclinical models from malignant effusions in patients with tyrosine kinase inhibitor resistant clear cell renal cell carcinoma. *Transl Oncol.* (corresponding author).
7. (2018) Lee JY, et al. Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract. *Transl Oncol.* (corresponding author).
8. (2018) Kim YS, et al. Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma. *BMC Urol.* (corresponding author).
9. (2019) Loriot Y, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. *N Engl J Med.*
10. (2020) Lee HW, et al. Single-cell RNA sequencing guides clever treatment strategies to overcome cancer evolution and ecology of resistance. *Genome Med.* (corresponding author).
11. (2020) Galsky, MD, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomized, placebo-controlled phase 3 trial. *Lancet.*
12. (2020) Powles T, et al. Avelumab as first-line maintenance therapy for locally advanced or metastatic urothelial carcinoma. *N Engl J Med.*
13. (2020) Lee HW, et al. A phase II trial of tipifarnib for patients with previously-treated, metastatic urothelial carcinoma harboring HRAS mutations. *Clin Cancer Res.* (corresponding author).
14. (2020) Powles T, et al. Durvalumab alone and durvalumab plus tremelimumab in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma: a randomized, open-label, multicentre, phase 3 trial (DANUBE). *Lancet Oncol.*
15. (2021) Bajorin D, et al. Adjuvant Nivolumab versus Placebo in High-Risk Muscle-Invasive Urothelial Carcinoma. *N Engl J Med.*
16. (2021) Choueiri TK, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. *N Engl J Med.*
17. (2022) Sung HH, et al. Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder. *Investig Clin Urol.* (corresponding author).
18. (2022) Kim R, et al. Genomic sequencing for bladder urothelial carcinoma and its clinical implications for immunotherapy. *Cancer Res Treat.* (corresponding author).
19. (2023) Kim H, et al. Neoadjuvant nivolumab plus gemcitabine/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of the bladder. *Cancer Res Treat.* (corresponding author).